Markets India
Quant Mutual Fund sold 20.81 lakh shares of Jubilant Pharmova worth Rs 190.47 crore in bulk deals, while Abakkus Four2Eight Opportunities Fund purchased 11 lakh shares. The transactions occurred as Jubilant Pharmova approved plans to raise up to Rs 800 crore through non-convertible debentures (NCDs).
Jubilant Pharmova's bulk share transactions and NCD fundraising plan reflect strategic capital management. Quant Mutual Fund reduced its stake from 1.85% to 0.54% by selling 20.81 lakh shares, with 11 lakh shares sold on the NSE at Rs 915 each, valued at Rs 100.65 crore, and 9,81,704 shares sold on the BSE at Rs 915.01, totaling Rs 89.82 crore. Abakkus Four2Eight Opportunities Fund acquired 11 lakh shares at Rs 915 each, valued at Rs 100.65 crore. The company's market cap stood at Rs 15,146.04 crore, with shares closing 2.04% higher at Rs 950.90.
The NCD issuance plan, which includes up to Rs 800 crore in debentures with a face value of Rs 1 lakh each, and a request for shareholder approval to issue up to Rs 2,500 crore in non-convertible debt, signals a broader debt-raising strategy. This could impact Jubilant Pharmova's debt-to-equity ratio and investor confidence, as the stock declined 8.80% in 2026.
Quant Mutual Fund and Abakkus Four2Eight Opportunities Fund are directly affected, with the latter gaining exposure. Shareholders face dilution risks, while the market may see increased debt issuance activity. Jubilant Pharmova's shares traded between Rs 908 and Rs 969.90, indicating mixed investor sentiment.
The company's board has approved the NCD issuance and debt authorization, but regulatory approvals remain pending. The success of the fundraising and market reaction to the debt load will determine the outcome of this capital strategy.
Jubilant Pharmova's board has approved the issuance of up to Rs 800 crore through NCDs and seeks shareholder authorisation to issue up to Rs 2,500 crore in non-convertible debt securities, subject to regulatory approvals.
Jubilant Pharmova's fundraising plan and stake sale highlight strategic capital management, but the success of the NCD issuance and market reaction to the debt load remain key uncertainties.
Topics: Stock Market, Debt Issuance, Mutual Fund Transactions, Non-Convertibles Debt, Shareholder Approval, Capital Management
#JubilantPharmova #NCDPlan #MutualFundTransactions #DebtIssuance #ShareholderApproval #CapitalManagement
Source: ET Markets
Post a Comment
Post a Comment